Food & Drug Administration (2024) Drug products or categories of drug products that present demonstrable difficulties for compounding under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act RIA (Proposed Rule), U.S
Human studies have confirmed that CJC-1295 produces statistically significant, dose-dependent, and sustained elevations in GH and IGF-1 levels [1][2]
It can affect multiple organ systems, including respiratory, cardiovascular, neurological, musculoskeletal and immunological, with the constellation of more than 200 possible symptoms varying from person to person and commonly including debilitating fatigue
Combined, the results are faster and more durable than either protocol alone
Walking, resistance bands, and bodyweight exercises all count
Our team can help explore savings programs and manufacturer copay assistance to make the treatment more affordable